Medicare’s Two-Step: Tax Dollars in, Bills Out

Picture this: you invest in a promising apple orchard, only to be charged full price at the market for the very apples your money helped grow. That’s the nimble shuffle our taxpayer dollars perform every time they back scientific breakthroughs, only to watch drug prices soar beyond reach. It’s a curious choreography where generosity ends up footing the bill twice. Pay to innovate, pay to medicate—rinse, repeat.

Here lies the elegant inconsistency: public funds fuel discovery, yet it’s private accounts that reap the rewards. Much like watching the orchestra outplay the maestro, pharmaceutical companies take a public encore with private results. Medicare, meanwhile, graciously steps in with taxpayer funds yet again, covering costs in a spectacle that could make even the slickest illusionist envious. Behold, the merry-go-round where public funds twist into private gains—a show where the audience pays for both the curtain and the act.